EASO issues a position statement on integrating incretin therapies into obesity care
A European obesity group says weight-loss drugs like Wegovy and Zepbound work best alongside diet, exercise, and mental health support, not as a stand-alone fix — but the guidance has no legal weight in the US.
The European Association for the Study of Obesity (EASO) has published a position statement in The Lancet Regional Health – Europe titled "Integrating incretin-based therapies into comprehensive obesity care" [1]. The paper lays out how GLP-1 and related incretin medicines should fit within broader obesity treatment rather than stand in for it [1].
The statement is framed as guidance for clinicians and health systems, covering how nutrition counseling, physical activity, psychological support, and long-term follow-up should accompany drug treatment [1]. It does not replace individual medical judgment, and it is a European professional society's position, not a rule from any government agency [1].
The specific numbers, dosing thresholds, or step-by-step protocols EASO recommends are not detailed in the material available here [1]. What is clear from the title and framing is the core message: incretin therapies are meant to be one part of a larger care plan, not the entire plan [1].
This distinction matters because incretin drugs — semaglutide, sold as Ozempic, Wegovy, and Rybelsus, and tirzepatide, sold as Mounjaro and Zepbound — have become widely used for weight loss and diabetes in recent years. EASO's statement pushes back on any idea that a prescription alone is sufficient, instead calling for support structures around the medicine [1].
Why it matters for patients
For people in the United States already taking or considering these drugs, this European statement carries no regulatory force [1]. The FDA, not EASO, sets US labeling and prescribing rules for semaglutide and tirzepatide products. Still, professional statements like this one often shape how doctors talk to patients about what a comprehensive treatment plan should include, even across borders.
The practical takeaway from the statement's framing is that drug treatment is described as most effective when combined with attention to diet, activity, and mental health, plus ongoing monitoring over time [1]. Patients weighing these medications may want to understand from their own prescriber what a full care plan looks like beyond the prescription itself, since that is the gap EASO's statement is meant to address [1].
It is also worth noting what is not established here. The statement as described does not appear to include US-specific data, insurance guidance, or details on cost and access, which remain separate and pressing issues for American patients regardless of what European professional bodies recommend [1]. Readers should not assume this statement changes anything about US drug labels, insurance coverage rules, or clinical guidelines from American bodies such as the American Diabetes Association or the Obesity Medicine Association, none of which are addressed in this source [1].
What happens next
The position statement was published in The Lancet Regional Health – Europe as of the article's posting [1]. It is not known from the available material whether US medical societies plan to issue a parallel or responsive statement, or whether the FDA will reference this document in any future guidance [1]. Readers following US practice standards should watch for statements from American obesity and endocrine societies, which would carry more direct relevance to prescribing here.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.